Phase 3 study · Jade Biosciences · NCT07902817
Jade Biosciences' phase 3 JADE101 study for IgA nephropathy
About 480 adults are planned. Participants get JADE101 every 8 weeks, JADE101 every 12 weeks or a placebo, and neither they nor the study team know which.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Jade Biosciences' phase 3 JADE101 study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your nephrologist.
1. Are you 18 or older?
2. Has a kidney biopsy confirmed your IgA nephropathy?
3. Is your latest urine protein at least 0.75g/g (UPCR), or at least 1g a day on a 24-hour urine test?
Your nephrologist's office can tell you your latest number.4. Is your eGFR, the kidney filtering number on your blood test, 30 or higher?
5. Have you taken an ACE inhibitor or ARB blood pressure medicine at the highest dose you can handle, steadily, for at least 12 weeks?
Examples are lisinopril and losartan.6. Have you ever taken an anti-APRIL, anti-CD38 or anti-CD20 medicine, including in another study?
Your doctor can tell you if any of your medicines are in these groups.The study team also checks for these, which are easier to go over with your nephrologist:
- IgA nephropathy caused by another condition, or IgA vasculitis that needs immunosuppressive treatment
- Rapidly progressive glomerulonephritis
- A long-lasting infection, such as chronic urinary tract or sinus infections, bronchiectasis or tuberculosis
- Body weight under 40kg (88 pounds), or severe obesity
- Recent steroids, immunosuppressive medicines or tonsil removal, within the study's washout period
- Another study medicine or a complement inhibitor in the past 30 days or longer
- Nephrotic syndrome now or in the past, and a low IgG antibody level
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- Jade Clinical SiteArvada, Colorado · Recruiting
- Jade Clinical SiteLauderdale Lakes, Florida · Recruiting
- Jade Clinical SiteAtlanta, Georgia · Recruiting
- Jade Clinical SiteKaty, Texas · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07902817.
Questions people ask about Jade Biosciences' phase 3 JADE101 study
Is Jade Biosciences' phase 3 JADE101 study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-11-03. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Jade Biosciences' phase 3 JADE101 study?
The listing names 4 US sites, in Colorado, Florida, Georgia, Texas. The full list is in the sites section of this page.
Who can join Jade Biosciences' phase 3 JADE101 study?
About 480 adults are planned. The main listed requirements are in the pre-check on this page, starting with: adults 18 and older. Only the study team decides who can join.
How do I contact the Jade Biosciences' phase 3 JADE101 study team?
The listing names this contact: JADE101 Study Contact, +1 781-201-4703, JADE101clinicaltrials@jadebiosciences.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Jade Biosciences. This page restates the public listing in plain words, and nothing here is medical advice; talk with your nephrologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07902817, last updated there 2026-11-03. Questions checked against the listing on November 9, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your nephrologist about whether a study is right for you.